Optimizing Treatment Strategies in mNSCLC
Thoracic oncology experts debate real-world decisions after platinum progression in metastatic non-small cell lung cancer (NSCLC)—how to manage diffuse progression on immunotherapy, strategies for oligoprogression, and the potential role of Tumor Treating Fields (TTFields) therapy in sequencing—highlighting practical considerations that inform daily practice.
Round 1
The Optimal Approach for Patients With Diffuse Progression on IO
The debate begins with diffuse progression on immunotherapy. The panelists explore whether to change treatment or add TTFields therapy, with discussion focused on benefit, toxicity, and quality of life.
Round 2
Managing Oligoprogression
The discussion turns to oligoprogression in the second round, with panelists debating the role of local radiotherapy, continuation of immunotherapy, and potential synergy with TTFields therapy. Key considerations include site selection, multidisciplinary input, and feasibility of treatment options.
Round 3
Sequencing in the Real-World Setting
In the third round, panelists consider when TTFields should be introduced, balancing arguments for early integration against calls for careful patient selection and individualized sequencing.
© 2025 HMP Global. All Rights Reserved.
This is a non-CME activity. The views and opinions expressed by the presenter(s) do not necessarily reflect the views and opinions of the Oncology Learning Network, HMP Global, or its employees and affiliates.
